Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04585490
Title Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Stanford University
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Durvalumab + Pemetrexed Disodium

Durvalumab

Carboplatin + Durvalumab + Paclitaxel

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.